The stock of Caribou Biosciences Inc (NASDAQ: CRBU) has decreased by -7.08 when compared to last closing price of 1.42. Despite this, the company has experienced a 3.09% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-28 that BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT.
Is It Worth Investing in Caribou Biosciences Inc (NASDAQ: CRBU) Right Now?
The 36-month beta value for CRBU is also noteworthy at 2.50. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRBU is 80.97M, and at present, short sellers hold a 13.53% of that float. The average trading volume of CRBU on June 26, 2025 was 1.13M shares.
CRBU’s Market Performance
CRBU stock saw an increase of 3.09% in the past week, with a monthly gain of 21.06% and a quarterly increase of 49.76%. The volatility ratio for the week is 10.80%, and the volatility levels for the last 30 days are 10.24% for Caribou Biosciences Inc (CRBU). The simple moving average for the past 20 days is 9.80% for CRBU’s stock, with a -11.12% simple moving average for the past 200 days.
Analysts’ Opinion of CRBU
Many brokerage firms have already submitted their reports for CRBU stocks, with Evercore ISI repeating the rating for CRBU by listing it as a “In-line.” The predicted price for CRBU in the upcoming period, according to Evercore ISI is $3 based on the research report published on June 03, 2024 of the previous year 2024.
Evercore ISI gave a rating of “Outperform” to CRBU, setting the target price at $13 in the report published on October 31st of the previous year.
CRBU Trading at 31.47% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBU starting from Haurwitz Rachel E., who purchase 20,000 shares at the price of $1.02 back on Mar 14 ’25. After this action, Haurwitz Rachel E. now owns 3,369,395 shares of Caribou Biosciences Inc, valued at $20,400 using the latest closing price.
MCCLUNG BARBARA G, the Chief Legal Officer of Caribou Biosciences Inc, sale 3,564 shares at $1.35 during a trade that took place back on Feb 21 ’25, which means that MCCLUNG BARBARA G is holding 443,502 shares at $4,811 based on the most recent closing price.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -21.62 for the present operating margin
- 0.73 for the gross margin
The net margin for Caribou Biosciences Inc stands at -19.55. The total capital return value is set at -0.67. Equity return is now at value -52.76, with -43.46 for asset returns.
Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -5.25.
Currently, EBITDA for the company is -166.62 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 15.74. The receivables turnover for the company is 3.92for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.63.
Conclusion
In summary, Caribou Biosciences Inc (CRBU) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
